Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation

Creative Commons License

Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., ...More

ANNALS OF ONCOLOGY, vol.33, 2022 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Abstract
  • Volume: 33
  • Publication Date: 2022
  • Doi Number: 10.1016/j.annonc.2022.02.139
  • Journal Name: ANNALS OF ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE